JP2025504519A5 - - Google Patents
Info
- Publication number
- JP2025504519A5 JP2025504519A5 JP2024543838A JP2024543838A JP2025504519A5 JP 2025504519 A5 JP2025504519 A5 JP 2025504519A5 JP 2024543838 A JP2024543838 A JP 2024543838A JP 2024543838 A JP2024543838 A JP 2024543838A JP 2025504519 A5 JP2025504519 A5 JP 2025504519A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- solvate
- pharmaceutically acceptable
- acceptable salt
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22305072.5 | 2022-01-24 | ||
| EP22305072 | 2022-01-24 | ||
| PCT/EP2023/051296 WO2023139182A1 (en) | 2022-01-24 | 2023-01-19 | Compound for use in preventing and/or treating an infection caused by sars-cov-2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025504519A JP2025504519A (ja) | 2025-02-12 |
| JP2025504519A5 true JP2025504519A5 (https=) | 2026-01-26 |
Family
ID=80446266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024543838A Pending JP2025504519A (ja) | 2022-01-24 | 2023-01-19 | Ｓａｒｓ－ｃｏｖ－２に起因する感染症の予防および／または処置における使用のための化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250099530A1 (https=) |
| EP (1) | EP4469073A1 (https=) |
| JP (1) | JP2025504519A (https=) |
| KR (1) | KR20240139056A (https=) |
| CN (1) | CN119072326A (https=) |
| WO (1) | WO2023139182A1 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2923160B1 (fr) | 2007-11-02 | 2013-07-26 | Pasteur Institut | Composes destines a prevenir ou traiter une infection virale. |
| WO2021228846A1 (en) | 2020-05-11 | 2021-11-18 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Compound for preventing or treating a viral infection |
| WO2022008597A1 (en) * | 2020-07-08 | 2022-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of infectious diseases |
| WO2022123062A1 (en) * | 2020-12-11 | 2022-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients |
-
2023
- 2023-01-19 EP EP23701435.2A patent/EP4469073A1/en active Pending
- 2023-01-19 JP JP2024543838A patent/JP2025504519A/ja active Pending
- 2023-01-19 WO PCT/EP2023/051296 patent/WO2023139182A1/en not_active Ceased
- 2023-01-19 CN CN202380017328.1A patent/CN119072326A/zh active Pending
- 2023-01-19 KR KR1020247024942A patent/KR20240139056A/ko active Pending
- 2023-01-19 US US18/730,927 patent/US20250099530A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021063088A5 (https=) | ||
| JP2006523216A5 (https=) | ||
| JP2024170583A5 (https=) | ||
| JP2004509061A5 (https=) | ||
| JP2024540183A5 (https=) | ||
| JP2022537047A5 (https=) | ||
| WO1995003056A1 (en) | Hepatitis c virus proliferation inhibitor | |
| JP2020507589A5 (https=) | ||
| WO2021195211A1 (en) | Quinoline compounds for treating respiratory disorders and viral infections | |
| JP2021521118A5 (https=) | ||
| TW202139987A (zh) | 維多氟地莫司(Vidofludimus)用於治療或預防病毒性疾病 | |
| JP4627356B2 (ja) | ウイルス性心筋炎の予防または治療薬剤 | |
| JP2021073257A5 (https=) | ||
| JP2024541569A5 (https=) | ||
| JP2019533660A5 (https=) | ||
| JP2022531251A5 (https=) | ||
| JPWO2023054732A5 (https=) | ||
| JP2022551691A5 (https=) | ||
| JP2025508656A5 (https=) | ||
| JP2022534776A5 (https=) | ||
| JP2025504519A5 (https=) | ||
| JP2022546424A5 (https=) | ||
| JP2023531930A5 (https=) | ||
| RU2417083C2 (ru) | Применение активаторов растворимой гуанилатциклазы для лечения острых и хронических легочных заболеваний | |
| JP2023525981A5 (https=) |